source
- AbbVie’s HS drug lutikizumab meets Phase 3 goal but falls short of analyst expectationsAbbVie reported that its investigational IL‑1α/β inhibitor lutikizumab achieved the primary endpoint in the Phase 3 INTREPID study for hidradenitis suppurativa, a chronic inflammatory skin disease…
- Merck and Moderna’s cancer vaccine data leak precedes official Phase 3 results releaseResults from the Phase 3 trial of Moderna and Merck’s therapeutic cancer vaccine were made public on Thursday after an earlier leak of the data. The vaccine, called intismeran autogene, is being e…